Phase II safety, tolerability, and dose selection study of isradipine as a potential disease-modifying intervention in early Parkinson's disease (STEADY-PD)

Movement Disorders

Volumn 28, Issue 13, 2013, Pages 1823-1831

  Tanya, Simuni ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Clinical trial; Disease modification; Isradipine; Parkinson's disease

Indexed keywords

AMANTADINE; ISRADIPINE; LEVODOPA; PLACEBO;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISABILITY; DISEASE COURSE; DIZZINESS; DOPAMINERGIC ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HOEHN AND YAHR SCALE; HUMAN; MALE; MULTICENTER STUDY; PARKINSON DISEASE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE;

CLINICAL TRIAL; DISEASE MODIFICATION; ISRADIPINE; PARKINSON'S DISEASE;

AGED; CALCIUM CHANNEL BLOCKERS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; ISRADIPINE; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PARKINSON DISEASE; SEVERITY OF ILLNESS INDEX;

EID: 84887625913     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.25639     Document Type: Article

References (19)

1. Chan CS, Guzman JN, Ilijic E, et al. "Rejuvenation" protects neurons in mouse models of Parkinson's disease. Nature 2007;447:1081-1086.
2. Braak H, Ghebremedhin E, Rub U, Bratzke H, Del Tredici K. Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res 2004;318:121-134.
3. Ilijic E, Guzman JN, Surmeier DJ. The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiol Dis 2011;43:364-371.
4. Kupsch A, Sautter J, Schwarz J, Riederer P, Gerlach M, Oertel WH. 1-Methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res 1996;741:185-196.
5. Sulzer D, Surmeier DJ. Neuronal vulnerability, pathogenesis, and Parkinson's disease. Mov Disord. 2013;28:41-50.
6. Becker C, Jick SS, Meier CR. Use of antihypertensives and the risk of Parkinson disease. Neurology 2008;70:1438-1444.
7. Ritz B, Rhodes SL, Qian L, Schernhammer E, Olsen JH, Friis S. L-type calcium channel blockers and Parkinson's disease in Denmark. Ann Neurol 2010;67:600-606.
8. Pasternak B, Svanstrom H, Nielsen NM, Fugger L, Melbye M, Hviid A. Use of calcium channel blockers and Parkinson's disease. Am J Epidemiol 2012;175:627-635.
9. Simuni T, Borushko E, Avram MJ, et al. Tolerability of isradipine in early Parkinson's disease: a pilot dose escalation study. Mov Disord 2010;25:2863-2866.
10. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181-184.
11. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
12. Beck AT, Beamesderfer A. Assessment of depression: the depression inventory. Mod Probl Pharmacopsychiatry 1974;7:151-169.
13. Goetz CG, Stebbins GT, Chmura TA, Fahn S, Klawans HL, Marsden CD. Teaching tape for the motor section of the unified Parkinson's disease rating scale. Mov Disord 1995;10:263-266.
14. Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-442.
15. Schwab RS EA. Projection technique for evaluating surgery in Parkinson's disease. In: Gillingham FJ DI, ed. Third Symposium on Parkinson's Disease. Edinburgh, Scotland: E & S Livingstone; 1969:152-157.
16. Peto V, Jenkinson C, Fitzpatrick R, Greenhall R. The development and validation of a short measure of functioning and well being for individuals with Parkinson's disease. Qual Life Res 1995;4:241-248.
17. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53:695-699.
18. Physician's Desk Reference (PDR) [online]. Available at: http://www.pdr.net/druginformation/DocumentSearchn_Local.aspx?DocumentID=32700580&DrugName=DynaCirc%20CR%20Controlled%20Release%20Tablets. Accessed February 10, 2013. Available at: http://www.pdrhealth.com/drugs/dynacirc-cr
19. Weir MR, Rosenberger C, Fink JC. Pilot study to evaluate a water displacement technique to compare effects of diuretics and ACE inhibitors to alleviate lower extremity edema due to dihydropyridine calcium antagonists. Am J Hypertens 2001;14:963-968.